• Aliases: CRA-032765, PCI-32765
    • An orally bioavailable, small-molecule inhibitor of BTK that binds to and irreversibly inhibits BTK activity
    • FDA approved for the treatment of MCL
    • Recommended dose: 420 to 560 mg PO daily with a full glass of water. No grapefruit juice or Seville orange
    • Half-life: 4 to 6 hours
    • Metabolism: CYP3A4 substrate and minor CYP2D6 substrate
    • Common side effects: US box warning: hemorrhage, infections, myelosuppression, renal toxicity, second primary malignancies, embryo–fetal toxicity, peripheral edema, rash, nausea/vomiting, diarrhea, fatigue, hyperuricemia, pancytopenia, abdominal pain/dyspepsia
    Other topics in Targeted and Immunotherapy Agents